Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3717-3723

  Pepper, Ruth ^a   Griffith, Megan ^a   Kirwan, Chris ^a   Levy, Jeremy ^a   Taube, David ^a   Pusey, Charles ^b   Lightstone, Liz ^b   Cairns, Tom ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Immunosuppression; Lupus nephritis; Mycophenolate mofetil; Rituximab; Steroids

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE CELLULITIS; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MORBIDITY; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 71049118062     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp336     Document Type: Article

References (35)

1. Donadio JV Jr, Hart GM, Bergstralh EJ et al. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995; 4: 109-115
2. Austin HA. Clinical evaluation and monitoring of lupus kidney disease. Lupus 1998; 7: 618-621
3. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophos-phamide. Arthritis Rheum 2002; 46: 2121-2131
4. Boumpas DT. Austin HA III, Fessler BJ et al. Systemic lupus erythe-matosus: emerging concepts Part I. Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 1995; 122: 940-950
5. Flanc RS, Roberts MA, Strippoli GF et al. Treatment of diffuse pro-liferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208
6. Font J, Ramos-Casals M, Cervera R et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. Q J Med 2001; 94: 19-26
7. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus ery-thematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415
8. Petri M. Detection of coronaryartery disease and the roleoftraditional risk factors in the Hopkins Lupus cohort. Lupus 2000; 9: 170-175
9. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257
10. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-839
11. Kingdon EJ, McLean AG, Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-611
12. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980
13. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 53: 2219-2228
14. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942
15. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5: 18-24
16. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-513
17. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effectsofRituximabinpatients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83
18. Smith KG, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and Vasculitis: Remission, relapse, and re-treatment Arthritis Rheum 2006, 54 2970-2982
19. Gunnarsson I, Sundelin B, Jónsdóttir T et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272
20. Weening JJ, D'Agati VD, Schwartz MM et al. for the International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisted. Kidney Int 2004; 65: 521-553
21. Borrows R, Chusney G, James A et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit 2005; 27: 442-450
22. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythe-matosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044-3056
23. Sutter JA, Kwan-Morley J, Dunham J et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 2008; 126: 282-290
24. Albert D, Dunham J, Khan S et al. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann Rheum Dis 2008; 67: 1724-1731
25. Genentech. Genentech and Biogen Idec announce top-line results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus. Genentech web site [online] 2008; http://www.gene.com/gene/news/press-releases/display.do? method= detail&id=11247
26. www.gene.com/gene/news/pressreleases/display.domethod=detail&id=11947
27. Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17: 191-197
28. Cambridge G, Isenberg DA, Edwards J et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011-1016
29. Camous L, Melander C, Vallet M et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kid Dis 2008; 52: 346-352
30. Korbet SM, Schwartz MM, Evans J et al. Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18: 244-254
31. Borrows R, Chusney G, Loucaidou M et al. Mycophenolic acid 12-h trough level monitoringinrenal transplantation: association with acute rejection and toxicity. Am J Transplant 2006; 6: 121-128
32. Neumann I, Haidinger M, Jäger H et al. Pharmacokinetics of my-cophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003; 14: 721-727
33. Neumann I, Fuhrmann H, Fang IF et al. Association between my-cophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008; 23: 3514-3520
34. Fervenza FC, Cosio FG, Erickson SB et al. Response to 'Rituximab in membranous nephropathy'. Kidney Int 2008; 74: 391-392
35. Anolik JH, Campbell D, Felgar RE et al. The relationship of Fcgam-maRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-459